<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577042</url>
  </required_header>
  <id_info>
    <org_study_id>RALATOR</org_study_id>
    <nct_id>NCT02577042</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen</brief_title>
  <official_title>Study of the Effect of Atorvastatin for Reducing &quot;Inflaming&quot; (Aging-related Complication) in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Physicians in charge of HIV-infected patients are increasingly being faced to previously&#xD;
      unrecognized comorbid conditions such as atherosclerosis and cardiovascular events, loss of&#xD;
      renal function, osteopenia/osteoporosis and bone fractures or non-AIDS-defining cancers&#xD;
      (1-4). The incidence of these conditions seems to be higher than in the general population&#xD;
      but there are controversial data about if these diseases appear at a younger age in&#xD;
      HIV-infected patients.&#xD;
&#xD;
      The investigators propose a strategy for treatment of elderly HIV-infected patients with a&#xD;
      double impact on systemic inflammation and age-related co-morbidities by switching the&#xD;
      protease inhibitors by raltegravir, a integrase inhibitor with a neutral effect on lipid and&#xD;
      bone metabolism, and adding an statin because of their anti-inflammatory effect. For safety&#xD;
      reasons, only patients with maintained viral suppression (documented indetectable viral load&#xD;
      for 1 year or more), and no history of virological failure to integrase inhibitors or&#xD;
      suspected or documented resistance mutations to the integrase or retrotranscriptase will be&#xD;
      candidates for the study.&#xD;
&#xD;
      Interleukin -6 and D-dimer are biomarkers that most strongly predict mortality in treated HIV&#xD;
      infection and sCD14, sCD163 are soluble markers of monocyte activation that reflect a key&#xD;
      source of inflammation and coagulation in HIV infection and predict mortality (26,27). For&#xD;
      that reasons, these markers were chosen to determine changes on them after the introduction&#xD;
      of the statin and the change of antiretrovirals&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Physicians in charge of HIV-infected patients are increasingly being faced to previously&#xD;
      unrecognized comorbid conditions such as atherosclerosis and cardiovascular events, loss of&#xD;
      renal function, osteopenia/osteoporosis and bone fractures or non-AIDS-defining cancers&#xD;
      (1-4).&#xD;
&#xD;
      The incidence of these conditions seems to be higher than in the general population but there&#xD;
      are controversial data about if these diseases appear at a younger age in HIV-infected&#xD;
      patients.&#xD;
&#xD;
      Different pathogenic mechanisms are involved in the increased risk of comorbidities. First,&#xD;
      the increased life expectancy of the HIV-infected population. The number of elderly HIV+&#xD;
      individuals is dramatically increasing, and nowadays, approximately one-half of the people&#xD;
      living with HIV in the United States are age 50 or older (5). In this sense, aging itself is&#xD;
      a condition associated with a chronic inflammation and immune senescence, contributing to&#xD;
      accelerate age-related morbidity. Second, the persistent inflammatory state and activation of&#xD;
      the immune system also induced by the HIV-infection, per se. This condition amplifies the&#xD;
      risk of age-related morbidity (6-9). Finally, antiretroviral-related toxicities contribute to&#xD;
      accelerate the apparition of some of these diseases such as the dyslipidemia and&#xD;
      cardiovascular events (mainly associated with the protease inhibitors use), renal damage or&#xD;
      low bone mineral density (especially by tenofovir and probably also by protease inhibitors).&#xD;
&#xD;
      As a consequence, one of the current aims of HIV management is the management of chronic&#xD;
      non-infectious co-morbidities in an increasingly older and more complex population. The use&#xD;
      of the newest and more safety antiretroviral drugs is a mandatory strategy, especially in&#xD;
      this elderly population, to achieve a maintained viral suppression. However, there are many&#xD;
      published studies showing higher levels of inflammation even in patients under a viral&#xD;
      suppression, in comparison with general population. Regarding this condition, the&#xD;
      investigators currently lack effective interventions to potently block this inflammatory&#xD;
      status. Although some initial data are published about this regard, data in elderly&#xD;
      HIV-infected people are lacking.&#xD;
&#xD;
      Based on these data, the investigators propose a strategy for treatment of elderly&#xD;
      HIV-infected patients with a double impact on systemic inflammation and age-related&#xD;
      co-morbidities by switching the protease inhibitors by raltegravir, a integrase inhibitor&#xD;
      with a neutral effect on lipid and bone metabolism, and adding an statin because of their&#xD;
      anti-inflammatory effect. For safety reasons, only patients with maintained viral suppression&#xD;
      (documented indetectable viral load for 1 year or more), and no history of virological&#xD;
      failure to integrase inhibitors or suspected or documented resistance mutations to the&#xD;
      integrase or retrotranscription will be candidates for the study.&#xD;
&#xD;
      Raltegravir is an antiretroviral drug that received approval by the U.S. Food and Drug&#xD;
      Administration (FDA) in 2007. It was the first of a new class of HIV drugs, the integrase&#xD;
      inhibitors, and exhibited rapid, potent and durable antiretroviral activity in antiretroviral&#xD;
      naïve patients and in treatment-experienced patients with drug-resistant HIV-1 (10-12).&#xD;
      Raltegravir has demonstrated a neutral effect on lipid and renal parameters, and a better&#xD;
      impact on bone mineral density (13) and lipid profile than protease inhibitors (14).&#xD;
&#xD;
      Statins are lipid-lowering drugs that also exert anti-inflammatory effects, and have&#xD;
      immune-modulatory properties. Recent studies in HIV-infected population have suggested that&#xD;
      statins have an anti-inflammatory effect, evaluated by inflammatory markers (15-21), and that&#xD;
      the statin use is associated with a lower risk of non-AIDS defining morbidities and&#xD;
      malignancies and mortality (22-25). But limited data have been published, mainly based on&#xD;
      retrospective studies, and no clinical recommendations are available. The investigators&#xD;
      propose the use of atorvastatin to study the anti-inflammatory effect measuring changes in&#xD;
      inflammatory markers and some clinical conditions. Atorvastatin was chosen due to the low&#xD;
      drug-drug interactions of this statin and ritonavir and the low cost. Since very few data are&#xD;
      available about the effect of statins on inflammatory markers and clinical conditions, a&#xD;
      intermediate dose (20 mg per day) was selected.&#xD;
&#xD;
      IL-6 and D-dimer are biomarkers that most strongly predict mortality in treated HIV infection&#xD;
      and sCD14, sCD163 are soluble markers of monocyte activation that reflect a key source of&#xD;
      inflammation and coagulation in HIV infection and predict mortality (26,27). For that&#xD;
      reasons, these markers were chosen to determine changes on them after the introduction of the&#xD;
      statin and the change of antiretrovirals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2015</start_date>
  <completion_date type="Actual">June 4, 2018</completion_date>
  <primary_completion_date type="Actual">June 4, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the Inflammatory Marker IL-6</measure>
    <time_frame>baseline, wk24 and wk72</time_frame>
    <description>Switching the PI by raltegravir, plus Kivexa or Truvada for 24 weeks. After that, atorvastatin, 20mg/day has been added for 48 weeks. (intergroup and intragroup)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Plasma Soluble Markers (D-dimer)</measure>
    <time_frame>baseline, wk24 and wk72</time_frame>
    <description>Changes in plasma soluble markers (D-dimer)</description>
  </primary_outcome>
  <other_outcome>
    <measure>Changes in the Inflammatory, Immune and Coagulation</measure>
    <time_frame>at week 72 from week 24 to assess the effect of statin</time_frame>
    <description>Changes in the inflammatory, immune and coagulation (intergroup and intragroup )</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in the Inflammatory, Immune and Coagulation</measure>
    <time_frame>at week 72 from baseline to assess the effect of PI or raltegravir plus statin</time_frame>
    <description>Compare intergroup and intragroup changes in the inflammatory, immune and coagulation</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in the Inflammatory, Immune and Coagulation</measure>
    <time_frame>at week 24 from baseline to asses the effect of PI or raltegravir</time_frame>
    <description>Compare intergroup and intragroup changes in the inflammatory, immune and coagulation</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Lipid Profile</measure>
    <time_frame>at week 72 from week 24 to assess the effect of statin</time_frame>
    <description>Compare intergroup and intragroup changes in lipid profile</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Lipid Profile</measure>
    <time_frame>at week 72 from baseline to assess the effect of PI or raltegravir plus statin</time_frame>
    <description>Compare intergroup and intragroup changes in lipid profile</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Lipid Profile</measure>
    <time_frame>at week 24 from baseline to asses the effect of PI or raltegravir</time_frame>
    <description>Compare intergroup and intragroup changes in lipid profile</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Lumbar and Femoral BMD and T-score Measured by DEXA</measure>
    <time_frame>at week 72 from week 24 to assess the effect of statin</time_frame>
    <description>Compare intergroup and intragroup changes in lumbar and femoral BMD and t-score measured by DEXA</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Lumbar and Femoral BMD and T-score Measured by DEXA</measure>
    <time_frame>at week 72 from baseline to assess the effect of PI or raltegravir plus statin</time_frame>
    <description>Compare intergroup and intragroup changes in lumbar and femoral BMD and t-score measured by DEXA</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Lumbar and Femoral BMD and T-score Measured by DEXA</measure>
    <time_frame>at week 24 from baseline to asses the effect of PI or raltegravir</time_frame>
    <description>Compare intergroup and intragroup changes in lumbar and femoral BMD and t-score measured by DEXA</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Bone Turnover Markers</measure>
    <time_frame>at week 72 from week 24 to assess the effect of statin</time_frame>
    <description>Compare intergroup and intragroup changes in bone turnover markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Bone Turnover Markers</measure>
    <time_frame>at week 72 from baseline to assess the effect of PI or raltegravir plus statin</time_frame>
    <description>Compare intergroup and intragroup changes in bone turnover markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Bone Turnover Markers</measure>
    <time_frame>at week 24 from baseline to asses the effect of PI or raltegravir</time_frame>
    <description>Compare intergroup and intragroup changes in bone turnover markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Renal Parameters</measure>
    <time_frame>at week 72 from week 24 to assess the effect of statin</time_frame>
    <description>Compare intergroup and intragroup changes in renal parameters</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Renal Parameters</measure>
    <time_frame>at week 72 from baseline to assess the effect of PI or raltegravir plus statin</time_frame>
    <description>Compare intergroup and intragroup changes in renal parameters</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare Intergroup and Intragroup Changes in Renal Parameters</measure>
    <time_frame>at week 24 from baseline to asses the effect of PI or raltegravir</time_frame>
    <description>Compare intergroup and intragroup changes in renal parameters</description>
  </other_outcome>
  <other_outcome>
    <measure>Viral Load &lt; 50 Copies</measure>
    <time_frame>at week 72</time_frame>
    <description>viral load &lt; 50 copies</description>
  </other_outcome>
  <other_outcome>
    <measure>Viral Load &gt; 50 Copies</measure>
    <time_frame>through study completion</time_frame>
    <description>viral load &gt; 50 copies</description>
  </other_outcome>
  <other_outcome>
    <measure>CD4+/CD8+ T Lymphocytes</measure>
    <time_frame>at week 72 from baseline</time_frame>
    <description>CD4+/CD8+ T lymphocytes</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Aging-related Inflammation in HIV-infected Patients</condition>
  <arm_group>
    <arm_group_label>Raltegravir + Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switching the PI by raltegravir, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PI-based regimen + Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.</description>
    <arm_group_label>Raltegravir + Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PI-based regimen</intervention_name>
    <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.</description>
    <arm_group_label>PI-based regimen + Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
    <arm_group_label>PI-based regimen + Atorvastatin</arm_group_label>
    <arm_group_label>Raltegravir + Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient having a diagnosis of HIV-1 infection.&#xD;
&#xD;
          -  Age 45 years old.&#xD;
&#xD;
          -  Current highly active antiretroviral therapy including Truvada or Kivexa plus a&#xD;
             ritonavir boosted PI started at least 3 months before.&#xD;
&#xD;
          -  Maintained undetectable plasma HIV-1 RNA (VL &lt; 50 copies/mL) for at least 12 months.&#xD;
&#xD;
          -  Voluntary written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of virological failure to integrase inhibitors.&#xD;
&#xD;
          -  Suspected or documented resistance mutations to the integrase, as well as NRTI-related&#xD;
             mutations that may impact nucleoside activity in current regimen.&#xD;
&#xD;
          -  Systemic concurrent process such as coinfection with hepatitis C or B, acute systemic&#xD;
             infection within the last 4 months, neoplasm, chronic inflammatory process, etc.&#xD;
&#xD;
          -  Treatment with other drugs with anti-inflammatory, anticoagulant or antiplatelet&#xD;
             effect (for instance corticosteroids, aspirin, etc…)&#xD;
&#xD;
          -  Therapy with statins within the last 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <results_first_submitted>June 3, 2020</results_first_submitted>
  <results_first_submitted_qc>June 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2020</results_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>protease inhibitors</keyword>
  <keyword>darunavir</keyword>
  <keyword>inflammation</keyword>
  <keyword>statins</keyword>
  <keyword>comorbidities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02577042/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir + Atorvastatin</title>
          <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>PI-based Regimen + Atorvastatin</title>
          <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir + Atorvastatin</title>
          <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>PI-based Regimen + Atorvastatin</title>
          <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" spread="3.5"/>
                    <measurement group_id="B2" value="51.8" spread="8.2"/>
                    <measurement group_id="B3" value="50.65" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Inflammatory Marker IL-6</title>
        <description>Switching the PI by raltegravir, plus Kivexa or Truvada for 24 weeks. After that, atorvastatin, 20mg/day has been added for 48 weeks. (intergroup and intragroup)</description>
        <time_frame>baseline, wk24 and wk72</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Inflammatory Marker IL-6</title>
          <description>Switching the PI by raltegravir, plus Kivexa or Truvada for 24 weeks. After that, atorvastatin, 20mg/day has been added for 48 weeks. (intergroup and intragroup)</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" lower_limit="34.5" upper_limit="50.1"/>
                    <measurement group_id="O2" value="40.0" lower_limit="36.9" upper_limit="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" lower_limit="34.6" upper_limit="49.8"/>
                    <measurement group_id="O2" value="41.1" lower_limit="36.1" upper_limit="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" lower_limit="36.8" upper_limit="52.9"/>
                    <measurement group_id="O2" value="41.7" lower_limit="34.7" upper_limit="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Plasma Soluble Markers (D-dimer)</title>
        <description>Changes in plasma soluble markers (D-dimer)</description>
        <time_frame>baseline, wk24 and wk72</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Plasma Soluble Markers (D-dimer)</title>
          <description>Changes in plasma soluble markers (D-dimer)</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1743" lower_limit="1459" upper_limit="1894"/>
                    <measurement group_id="O2" value="1990" lower_limit="1574" upper_limit="2523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>wk24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1844" lower_limit="1547" upper_limit="2340"/>
                    <measurement group_id="O2" value="1917" lower_limit="1552" upper_limit="2244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>wk72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2051" lower_limit="1656" upper_limit="2414"/>
                    <measurement group_id="O2" value="1868" lower_limit="1438" upper_limit="2175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in the Inflammatory, Immune and Coagulation</title>
        <description>Changes in the inflammatory, immune and coagulation (intergroup and intragroup )</description>
        <time_frame>at week 72 from week 24 to assess the effect of statin</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Inflammatory, Immune and Coagulation</title>
          <description>Changes in the inflammatory, immune and coagulation (intergroup and intragroup )</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in the Inflammatory, Immune and Coagulation</title>
        <description>Compare intergroup and intragroup changes in the inflammatory, immune and coagulation</description>
        <time_frame>at week 72 from baseline to assess the effect of PI or raltegravir plus statin</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in the Inflammatory, Immune and Coagulation</title>
          <description>Compare intergroup and intragroup changes in the inflammatory, immune and coagulation</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in the Inflammatory, Immune and Coagulation</title>
        <description>Compare intergroup and intragroup changes in the inflammatory, immune and coagulation</description>
        <time_frame>at week 24 from baseline to asses the effect of PI or raltegravir</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in the Inflammatory, Immune and Coagulation</title>
          <description>Compare intergroup and intragroup changes in the inflammatory, immune and coagulation</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Lipid Profile</title>
        <description>Compare intergroup and intragroup changes in lipid profile</description>
        <time_frame>at week 72 from week 24 to assess the effect of statin</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Lipid Profile</title>
          <description>Compare intergroup and intragroup changes in lipid profile</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Lipid Profile</title>
        <description>Compare intergroup and intragroup changes in lipid profile</description>
        <time_frame>at week 72 from baseline to assess the effect of PI or raltegravir plus statin</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Lipid Profile</title>
          <description>Compare intergroup and intragroup changes in lipid profile</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Lipid Profile</title>
        <description>Compare intergroup and intragroup changes in lipid profile</description>
        <time_frame>at week 24 from baseline to asses the effect of PI or raltegravir</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Lipid Profile</title>
          <description>Compare intergroup and intragroup changes in lipid profile</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Lumbar and Femoral BMD and T-score Measured by DEXA</title>
        <description>Compare intergroup and intragroup changes in lumbar and femoral BMD and t-score measured by DEXA</description>
        <time_frame>at week 72 from week 24 to assess the effect of statin</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Lumbar and Femoral BMD and T-score Measured by DEXA</title>
          <description>Compare intergroup and intragroup changes in lumbar and femoral BMD and t-score measured by DEXA</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Lumbar and Femoral BMD and T-score Measured by DEXA</title>
        <description>Compare intergroup and intragroup changes in lumbar and femoral BMD and t-score measured by DEXA</description>
        <time_frame>at week 72 from baseline to assess the effect of PI or raltegravir plus statin</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Lumbar and Femoral BMD and T-score Measured by DEXA</title>
          <description>Compare intergroup and intragroup changes in lumbar and femoral BMD and t-score measured by DEXA</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Lumbar and Femoral BMD and T-score Measured by DEXA</title>
        <description>Compare intergroup and intragroup changes in lumbar and femoral BMD and t-score measured by DEXA</description>
        <time_frame>at week 24 from baseline to asses the effect of PI or raltegravir</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Lumbar and Femoral BMD and T-score Measured by DEXA</title>
          <description>Compare intergroup and intragroup changes in lumbar and femoral BMD and t-score measured by DEXA</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Bone Turnover Markers</title>
        <description>Compare intergroup and intragroup changes in bone turnover markers</description>
        <time_frame>at week 72 from week 24 to assess the effect of statin</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Bone Turnover Markers</title>
          <description>Compare intergroup and intragroup changes in bone turnover markers</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Bone Turnover Markers</title>
        <description>Compare intergroup and intragroup changes in bone turnover markers</description>
        <time_frame>at week 72 from baseline to assess the effect of PI or raltegravir plus statin</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Bone Turnover Markers</title>
          <description>Compare intergroup and intragroup changes in bone turnover markers</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Bone Turnover Markers</title>
        <description>Compare intergroup and intragroup changes in bone turnover markers</description>
        <time_frame>at week 24 from baseline to asses the effect of PI or raltegravir</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Bone Turnover Markers</title>
          <description>Compare intergroup and intragroup changes in bone turnover markers</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Renal Parameters</title>
        <description>Compare intergroup and intragroup changes in renal parameters</description>
        <time_frame>at week 72 from week 24 to assess the effect of statin</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Renal Parameters</title>
          <description>Compare intergroup and intragroup changes in renal parameters</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Renal Parameters</title>
        <description>Compare intergroup and intragroup changes in renal parameters</description>
        <time_frame>at week 72 from baseline to assess the effect of PI or raltegravir plus statin</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Renal Parameters</title>
          <description>Compare intergroup and intragroup changes in renal parameters</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compare Intergroup and Intragroup Changes in Renal Parameters</title>
        <description>Compare intergroup and intragroup changes in renal parameters</description>
        <time_frame>at week 24 from baseline to asses the effect of PI or raltegravir</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Intergroup and Intragroup Changes in Renal Parameters</title>
          <description>Compare intergroup and intragroup changes in renal parameters</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Viral Load &lt; 50 Copies</title>
        <description>viral load &lt; 50 copies</description>
        <time_frame>at week 72</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load &lt; 50 Copies</title>
          <description>viral load &lt; 50 copies</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Viral Load &gt; 50 Copies</title>
        <description>viral load &gt; 50 copies</description>
        <time_frame>through study completion</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load &gt; 50 Copies</title>
          <description>viral load &gt; 50 copies</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CD4+/CD8+ T Lymphocytes</title>
        <description>CD4+/CD8+ T lymphocytes</description>
        <time_frame>at week 72 from baseline</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Atorvastatin</title>
            <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PI-based Regimen + Atorvastatin</title>
            <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+/CD8+ T Lymphocytes</title>
          <description>CD4+/CD8+ T lymphocytes</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to week 72</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir + Atorvastatin</title>
          <description>Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks&#xD;
Raltegravir: Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>PI-based Regimen + Atorvastatin</title>
          <description>Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.&#xD;
PI-based regimen: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.&#xD;
Atorvastatin: Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>DAIDS AE GRADING TA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>increments of creatine kinase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increment of liver enzymes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Fundació Lluita contra la SIDA</organization>
      <phone>+34 93 497 84 14</phone>
      <email>enegredo@flsida.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

